Terence Flynn
Stock Analyst at Morgan Stanley
(4.13)
# 442
Out of 5,179 analysts
240
Total ratings
53.97%
Success rate
11.6%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Overweight | $33 → $38 | $24.80 | +53.23% | 4 | Mar 20, 2026 | |
| BNTX BioNTech SE | Maintains: Overweight | $134 → $125 | $85.68 | +45.89% | 6 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $570 → $596 | $433.07 | +37.62% | 4 | Mar 10, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,290 → $1,313 | $878.24 | +49.50% | 24 | Feb 5, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $209.40 | +28.94% | 20 | Feb 5, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $304 → $309 | $348.77 | -11.40% | 12 | Feb 4, 2026 | |
| JNJ Johnson & Johnson | Upgrades: Overweight | $200 → $262 | $240.45 | +8.96% | 28 | Jan 28, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $23 → $20 | $20.28 | -1.38% | 9 | Jan 8, 2026 | |
| NRIX Nurix Therapeutics | Upgrades: Overweight | $15 → $36 | $14.76 | +143.90% | 7 | Jan 8, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $26 → $21 | $8.37 | +150.90% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $27 | $27.04 | -0.15% | 21 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $37 | $58.54 | -36.80% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $119.63 | -14.74% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $45.92 | +172.21% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $5.84 | +54.11% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $46.35 | +16.50% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $522.83 | -16.80% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $10.10 | +8.91% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $45.75 | -30.05% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $12.37 | -11.08% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.41 | +231.95% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $183.84 | +137.16% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $317.36 | - | 2 | Oct 2, 2017 |
Alumis
Mar 20, 2026
Maintains: Overweight
Price Target: $33 → $38
Current: $24.80
Upside: +53.23%
BioNTech SE
Mar 11, 2026
Maintains: Overweight
Price Target: $134 → $125
Current: $85.68
Upside: +45.89%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Overweight
Price Target: $570 → $596
Current: $433.07
Upside: +37.62%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,290 → $1,313
Current: $878.24
Upside: +49.50%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $209.40
Upside: +28.94%
Amgen
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $304 → $309
Current: $348.77
Upside: -11.40%
Johnson & Johnson
Jan 28, 2026
Upgrades: Overweight
Price Target: $200 → $262
Current: $240.45
Upside: +8.96%
Arcus Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $20.28
Upside: -1.38%
Nurix Therapeutics
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $14.76
Upside: +143.90%
Biohaven
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $8.37
Upside: +150.90%
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $27.04
Upside: -0.15%
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $58.54
Upside: -36.80%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $119.63
Upside: -14.74%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $45.92
Upside: +172.21%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $5.84
Upside: +54.11%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $46.35
Upside: +16.50%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $522.83
Upside: -16.80%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $10.10
Upside: +8.91%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $45.75
Upside: -30.05%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $12.37
Upside: -11.08%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.41
Upside: +231.95%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $183.84
Upside: +137.16%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $317.36
Upside: -